Active Older Adult Program on Health and Well-being

Older Adult Clinical Trial

Official title:

The Effects of an Active Older Adult Program at the Dan Abraham Healthy Living Center on Health and Well-being

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04897373
• Other study ID #: 18-001769
• Status: Completed
• Start date: August 7, 2018
• Est. completion date: April 2, 2020

Study information

• Verified date: May 2021
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether a structured 12-week program designed for older adults will improve physical function and, in parallel, circulating biomarkers of aging

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: April 2, 2020
• Est. primary completion date: April 2, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Men and women age 55 years or older.
• Membership at the DAHLC.
• New to AOA (Active Older Adult) Program and commitment to full participation in the twelve-week program.
• Must be able to get down and off the floor with little assistance.

Exclusion Criteria:

• Inability to provide informed consent.
• Previous participation in the AOA Program at the DAHLC.

Related Conditions & MeSH terms

• Older Adult

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in repeated chair rise time	Chair stand test where participants will perform a chair rise movement for five repetitions. The series of 5 repetitions will be timed and measured in seconds.	Baseline to end of study, approximately 14 weeks
Primary	Change in plasma protein levels reflective of biological age	Blood samples will be obtained at baseline and at 12 weeks. The concentration of target proteins (pg/mL) in the plasma will be measured and compared between baseline and week 12.	Baseline, week 12
Primary	Change in expression of senescence-related genes in blood cells	Blood samples will be obtained at baseline and at 12 weeks. The expression of senescence-related genes (arbitrary units) will be measured in immune cells isolated from whole blood and compared between baseline and week 12.	Baseline, week 12
Secondary	Change in Self-reported Physical Function	Measured using the Physical Component Scale (PCS) from the 12-Item short form general health survey (SF-12).	Baseline, week 12
Secondary	Change in Performance-based Physical Function	Measured using the timed up-and-go test (seconds to complete).	Baseline, week 12
Secondary	Change in Mental Function	Measured using the Mental Component Scale (MCS) from the 12-Item short form general health survey (SF-12)	Baseline, week 12
Secondary	Change in self-assessment of well-being	Measured using a linear analogue self-assessment scale of well-being from 0 ("as bad as it can be") to 10 ("as good as it can be") of mental, physical, emotional, and spiritual well-being, level of social activity, and overall quality of life during the past week	Baseline, week 12

External Links

•   Mayo Clinic Clinical Trials